AVANIR Pharmaceuticals (FRA:AV2B) Retained Earnings : €-427.55 Mil (As of Sep. 2014)

View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. AVANIR Pharmaceuticals's retained earnings for the quarter that ended in Sep. 2014 was €-427.55 Mil.

AVANIR Pharmaceuticals's quarterly retained earnings declined from Mar. 2014 (€-378.97 Mil) to Jun. 2014 (€-395.13 Mil) and declined from Jun. 2014 (€-395.13 Mil) to Sep. 2014 (€-427.55 Mil).

AVANIR Pharmaceuticals's annual retained earnings declined from Sep. 2012 (€-329.85 Mil) to Sep. 2013 (€-374.40 Mil) and declined from Sep. 2013 (€-374.40 Mil) to Sep. 2014 (€-427.55 Mil).

AVANIR Pharmaceuticals Retained Earnings Historical Data

The historical data trend for AVANIR Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals Retained Earnings Chart

AVANIR Pharmaceuticals Annual Data

Trend

Sep05

Sep06

Sep07

Sep08

Sep09

Sep10

Sep11

Sep12

Sep13

Sep14

Retained Earnings

Get a 7-Day Free Trial

-232.48

-265.59

-329.85

-374.40

-427.55

AVANIR Pharmaceuticals Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Retained Earnings	Get a 7-Day Free Trial															-374.40	-373.38	-378.97	-395.13	-427.55

AVANIR Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

AVANIR Pharmaceuticals (FRA:AV2B) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » Retained Earnings

Traded in Other Exchanges

N/A

Address

Website

http://www.avanir.com

Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines